Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet (R) International Outcome Study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11130%2F18%3A10375260" target="_blank" >RIV/00216208:11130/18:10375260 - isvavai.cz</a>

Alternative codes found

RIV/00064203:_____/18:10375260

Result on the web

<a href="https://doi.org/10.1515/jpem-2017-0489" target="_blank" >https://doi.org/10.1515/jpem-2017-0489</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1515/jpem-2017-0489" target="_blank" >10.1515/jpem-2017-0489</a>

Result language

angličtina

Original language name

Still too little, too late? Ten years of growth hormone therapy baseline data from the NordiNet (R) International Outcome Study

Original language description

Background: We investigated time trends in age, gender, growth hormone (GH) dose and height standard deviation score (SDS) in children with GH deficiency (GHD), born small for gestational age (SGA) or with Turner syndrome (TS) starting GH treatment. Methods: Data were obtained from children enrolled in the NordiNet (R) International Outcome Study (IOS) between 2006 and 2015 in the Czech Republic, France, Germany, Serbia and Montenegro (all indications), and Switzerland and the UK (GHD only). Trends were analyzed by linear regression. Patients were divided by age into early-, medium-or late-start groups in three different time periods. Results: Approximately one-third of children starting treatment for GHD were girls, with no apparent increase in proportion over time. The mean baseline age for starting treatment decreased significantly (p &lt; 0.001) for both GHD and SGA in the Czech Republic and Germany. In the other countries studied, over 40% of children started treatment for GHD and SGA late (girls &gt;10, boys &gt;11 years) between 2013 and 2015. The mean baseline GH doses were largely within recommended ranges for GHD and SGA, but below the lowest recommended starting dose for TS in almost every year since 2011 except in France. Conclusions: Approximately one-third of children starting treatment for GHD were girls. Between 2013 and 2015, more than 40% of children started treatment for GHD and SGA late except in Germany and the Czech Republic. TS patients received below-recommended doses. These results highlight the need for earlier identification of short stature in children, particularly girls, and for dose optimization in TS.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30202 - Endocrinology and metabolism (including diabetes, hormones)

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Journal of Pediatric Endocrinology &amp; Metabolism

ISSN

0334-018X

e-ISSN

—

Volume of the periodical

31

Issue of the periodical within the volume

5

Country of publishing house

DE - GERMANY

Number of pages

12

Pages from-to

521-532

UT code for WoS article

000431124900006

EID of the result in the Scopus database

2-s2.0-85045875005